Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Hiromichi Ebi's publication output changed over time?
ScholarIQpublication output · 2007–2024
Output grew0% over the shown period — from 1 works in 2007 to 1 in 2024.
1
2
3
1
1
1
1
1
20072011201220172019202020212024
What are the most-cited papers on Hiromichi Ebi?
ScholarIQmost cited works
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran, Hiromichi Ebi, Alexa B. Turke, Erin M. Coffee, Michiya Nishino, Alexandria P. Cogdill, Ronald D. Brown, Patricia Della Pelle, Dora Dias‐Santagata, Kenneth E. Hung, Keith T. Flaherty, Adriano Piris, Jennifer A. Wargo, Jeffrey Settleman, Mari Mino–Kenudson, Jeffrey A. Engelman
Cancer Discovery. 20121,032 CitationsOPEN ACCESS
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Takayuki Yoshino, Dirk Arnold, Hiroya Taniguchi, George Pentheroudakis, Kentaro Yamazaki, Rui‐Hua Xu, Tae‐Woo Kim, Muhammad Ismail, Iain Tan, Kun‐Huei Yeh, Axel Grothey, S. Zhang, Joong Bae Ahn, M.Y. Mastura, Dawn Q. Chong, Liqun Chen, Scott Kopetz, Takako Eguchi-Nakajima, Hiromichi Ebi, Atsushi Ohtsu, Andrés Cervantes, Kei Muro, Josep Tabernero, Hironobu Minami, Fortunato Ciardiello, Jean‐Yves Douillard
Annals of Oncology. 2017596 CitationsOPEN ACCESS
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama, Tahsin M. Khan, Cyril H. Benes, Eugene Lifshits, Hiromichi Ebi, Victor M. Rivera, William C. Shakespeare, A. John Iafrate, Jeffrey A. Engelman, Alice T. Shaw
Proceedings of the National Academy of Sciences. 2011542 CitationsOPEN ACCESS
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Chen Zhao, Katherine A. Cheng, Zandra E. Walton, Yuchuan Wang, Hiromichi Ebi, Takeshi Shimamura, Yan Liu, Tanya Tupper, Jing Ouyang, Jie Li, Peng Gao, Michele Sue‐Ann Woo, Chunxiao Xu, Masahiko Yanagita, Abigail Altabef, Shumei Wang, Charles Lee, Yuji Nakada, Christopher G. Peña, Yanping Sun, Yoko Franchetti, Catherine Yao, Amy Saur, Michael D. Cameron, Mizuki Nishino, D. Neil Hayes, Matthew D. Wilkerson, Patrick J. Roberts, Carrie B. Lee, Nabeel Bardeesy, Mohit Butaney, Lucian R. Chirieac, Daniel B. Costa, David M. Jackman, Norman E. Sharpless, Diego H. Castrillón, George D. Demetri, Pasi A. Jänne, Pier Paolo Pandolfi, Lewis C. Cantley, Andrew L. Kung, Jeffrey A. Engelman, Kwok‐Kin Wong
Nature. 2012452 Citations
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Kenneth E. Hung, Toshi Shioda, Dora Dias‐Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino–Kenudson, Kwok‐Kin Wong, Jeffrey A. Engelman
S25671836. 2012383 CitationsOPEN ACCESS
Related on ScholarIQ
Aichi Cancer Center
Institution
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Paper
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Paper
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Paper
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Paper
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Paper